Phase I study of combination recombinant interleukin-2 and interferon gamma in patients with advanced malignancies.
A phase I trial of interleukin-2 and interferon gamma combination treatment in patients with advanced malignancies was performed based on preclinical in vitro and in vivo data which demonstrated synergistic antitumor effect. The toxicities, immune parameters, and tumor responses are described. The clinical and biologic maximal tolerated doses were extrapolated from these data.
Hu
E
E
Department of Hematology/Oncology, University of Southern California School of Medicine, Los Angeles.
Watkins
K
K
Groshen
S
S
Chen
S C
SC
Malloy
B
B
Agah
R
R
Nichols
P
P
Parker
J
J
Martin
A
A
Boosalis
M G
MG
D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007107:Immune System / Q000187:drug effects; D007371:Interferon-gamma / Q000008:administration & dosage* / Q000009:adverse effects; D007376:Interleukin-2 / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy*; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use
D007376:Interleukin-2; D011994:Recombinant Proteins; D007371:Interferon-gamma